46O Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
| Autor: | Dai, M.S., Feng, Y.H., Chen, S.W., Masuda, N., Sangai, T., Yau, T., Kwong, A., Ngan, R., Yap, Y.S., Ang, P.C.S., Ow, S., Lee, K.S., Kim, S.B., Chung, H.C., Keyvanjah, K., Bebchuk, J., Chen, M-C.J. |
|---|---|
| Zdroj: | In Annals of Oncology November 2020 31 Supplement 6:S1259-S1259 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|